Photo ©iStock/LightFieldStudios

(05/27/2026) William S. Middleton Veterans’ Hospital and University of Wisconsin researchers identified a potential new treatment option for melanoma, the most dangerous form of skin cancer. Researchers first learned that an enzyme called SIRT3 is essential to the life cycle of melanoma cancer cells. Then, using tissue samples and mouse models, they showed that blocking SIRT3 production reduced tumor growth and cell colony formation. Furthermore, applying a compound that inhibited both SIRT3 and the related enzyme SIRT1 significantly decreased tumor volume and weight, suggesting combined targeting of these two enzymes could be a promising new therapeutic target for this deadly form of skin cancer. (Journal of Dermo-Oncology, Apr. 14, 2026)